Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis

Nature Clinical Practice Neurology

Volumn 4, Issue 11, 2008, Pages 600-609

  Henchcliffe, Claire ^a   Beal, Flint M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; CREATINE; CYTOCHROME C; CYTOCHROME C OXIDASE; DJ 1 PROTEIN; DNA DIRECTED DNA POLYMERASE GAMMA; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PARAQUAT; PARKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE INDUCED PUTATIVE KINASE 1; PHOSPHOTRANSFERASE; PLACEBO; PROTEIN BAX; RASAGILINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RESVERATROL; ROTENONE; SERINE PROTEINASE OMI; SIRTUIN 1; TRICHLOROETHYLENE; UBIDECARENONE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIOXIDANT ACTIVITY; APOPTOSIS; BRAIN MITOCHONDRION; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TOLERABILITY; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; EXCITOTOXICITY; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; MELAS SYNDROME; MERRF SYNDROME; MITOCHONDRIAL RESPIRATION; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW;

ANIMALS; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; PARKINSON DISEASE; UBIQUINONE; VITAMINS;

EID: 55849122639     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0924     Document Type: Review

References (93)

1. Beal MF (2007) Mitochondria and neurodegeneration. Novartis Found Symp 287: 183-192
2. Schapira AH (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 7: 97-109
3. Schapira AH et al. (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54: 823-827
4. Parker WD Jr et al. (2008) Complex I deficiency in Parkinson's disease frontal cortex. Brain Res 1189: 215-218
5. Keeney PM et al. (2006) Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26: 5256-5264
6. Haas RH et al. (1995) Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 37: 714-722
7. Penn AM et al. (1995) Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle. Neurology 45: 2097-2099
8. Swerdlow RH et al. (1996) Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40: 663-671
9. Gu M et al. (1998) Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 44: 177-186
10. 18FDG-PET study. Brain 123: 340-352
11. Rango M et al. (2005) Parkinson's disease and brain mitochondrial dysfunction: A functional phosphorus magnetic resonance spectroscopy study. J Cereb Blood Flow Metab 26: 283-290
12. Bowen BC et al. (1995) Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J Neuroradiol 16: 61-68
13. Henchcliffe C et al.: Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial function in Parkinson's disease. Ann N Y Acad Sci, in press
14. Dexter DT et al. (1989) Basal lipid paroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389
15. Zhang J et al. (1999) Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154: 1423-1429
16. Perry TL et al. (1986) Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67: 269-274
17. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53 (Suppl 3): S26-S36
18. Bogdanov M et al. (2008) Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131: 389-396
19. Weisskopf MG et al. (2007) Plasma urate and risk of Parkinson's disease. Am J Epidemiol 166: 561-567
20. Green DR et al. (2004) The pathophysiology of mitochondrial cell death. Science 305: 626-629
21. Beal MF (1998) Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 44 (Suppl 1): S110-S114
22. Langston JW et al. (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980
23. Betarbet R et al. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306
24. Coulom H et al. (2004) Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogastar. J Neurosci 24: 10993-10998
25. Cicchetti F et al. (2005) Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats. Neurobiol Dis 20: 360-371
26. Greenamyre JT et al. (1994) Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 35: 655-661
27. Swerdlow RH et al. (1998) Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol 44: 873-881
28. Wooten GF et al. (1997) Maternal inheritance in Parkinson's disease. Ann Neurol 41: 265-268
29. Simon DK et al. (1999) Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation. Neurology 53: 1787-1793
30. Luoma P et al. (2004) Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: Clinical and molecular genetic study. Lancet 364: 875-882
31. Bender A et al. (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38: 515-517
32. Srivastava S et al. (2005) Double-strand breaks of mouse muscle mtDNA promote large deletions similar to multiple mtDNA deletions in humans. Hum Mol Genet 14: 893-902
33. Pyle A et al. (2005) Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann Neurol 57: 564-567
34. Devi L et al. (2008) Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283:9089-9100
35. Cole NB et al. (2008) Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp Cell Res 314: 2076-2089
36. Shavali S et al. (2008) Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neurosci Lett 439: 125-128
37. Martin LJ et al. (2006) Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26:41-50
38. Parihar MS et al. (2008) Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mal Life Sci 65 1272-1284
39. Buttner S et al. (2008) Functional mitochondria are required for α-synuclein toxicity in aging yeast. J Biol Chem 283: 7554-7560
40. Dauer W et al. (2003) Parkinson's disease: Mechanisms and models. Neuron 39: 889-909
41. Song DD et al. (2004) Enhanced substantia nigra mitochondrial pathology in human α-synuclein transgenic mice after treatment with MPTP. Exp Neurol 186: 158-172
42. Kuroda Y et al. (2006) Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 15: 883-895
43. Greene JC et al. (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophile parkin mutants. Proc Natl Acad Sci USA 100: 4078-4083
44. Pesah Y et al. (2004) Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131: 2183-2194
45. Palacino JJ et al. (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279: 18614-18622
46. Muftuoglu M et al. (2004) Mitochondrial complex I and IV activities in leukocytes; from patients with parkin mutations. Mov Disord 19: 544-548
47. Poole AC et al. (2008) The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 105: 1638-1643
48. Silvestri L et al. (2005) Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 14: 3477-3492
49. Pridgeon JW et al. (2007) PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 5 e172
50. Hoepken HH et al. (2007) Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol Dis 25: 401-411
51. Clark IE et al. (2006) Drosophila Pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441: 1162-1166
52. Yang Y et al. (2008) Pink1 regulates mitochondriall dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci USA 105: 7070-7075
53. Petit A et al. (2005) Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem 280: 34025-34032
54. Wood-Kaczmar A et al. (2008) PINK1 is necessary for long term survival and mitochondriall function in human dopaminergic neurons. PLoS ONE 3: E2455
55. Exner N et al. (2007) Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 27: 12413-12418
56. Bonifati V et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 256-259
57. Yokota T et al. (2003) Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun 312: 1342-1348
58. Zhang L et al. (2005) Mitochondrial localization of the Parkinson's disease related protein DJ-1: Implications for pathogenesis. Hum Mol Genet 14: 2063-2073
59. Canet-Aviles RM et al. (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 101: 9103-9108
60. Meulener M et al. (2005) Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr Biol 15: 1572-1577
61. Park J et al. (2005) Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. Gene 361: 133-139
62. Yang Y et al. (2005) Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci USA 102: 13670-13675
63. Shendelman S et al. (2004) DJ-1 is a redox-dependent molecular chaperone that inhibits α-synuclein aggregate formation. PLoS Biol 2: E362
64. Meulener MC et al. (2005) DJ-1 is present in a large molecular complex in human brain tissue and interacts with a-synuclein. J Neurochem 93: 1524-1532
65. West AB et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102: 16842-16847
66. Martins LM et al. (2004) Neuroprotective role of the Reaper-related serline protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 24: 9848-9862
67. Strauss KM et al. (2005) Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 14: 2099-2111
68. Ravagnan L et al. (2002) Mitochondria, the killer organelles and their weapons. J Cell Physiol 192: 131-137
69. Plun-Favreau H et al. (2007) The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol 9: 1243-1252
70. Simon-Sanchez J et al. (2008) Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum Mol Genet 17: 1988-1993
71. Beal MF (2004) Mitochondriall dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 36: 381-386
72. McCarthy S et al. (2004) Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble coenzyme Q10. Toxicol Appl Pharmacol 201: 21-31
73. Menke T et al. (2003) Coenzyme Q10 reduces the toxicity of rotenone in neuronal cultures by preserving the mitochondriall membrane potential. Biofactors 18: 65-72
74. Beal MF et al. (1998) Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 783: 109-114
75. Horvath TL et al. (2003) Coenzyme Q induces nigral mitochondrial uncoupling and prevents nigral cell loss in a primate model of Parkinson's disease. Endocrinology 144: 2757-2760
76. Stamelou M et al. (2008) Short-term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo-controlled trial. Mov Disord 23: 942-949
77. Shults CW et al. (2002) Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch Neurol 59: 1541-1550
78. The NINDS NET-PD Investigators (2007) A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68: 20-28
79. The NINDS NET-PD Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66: 664-671
80. Klivenyi P et al. (2006) Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis 21: 541-548
81. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 561-566
82. Lagouge M et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127: 1109-1122
83. Lu KT et al. (2008) Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J Agric Food Chem 56:.6910-6913
84. Ko L et al. (2000) Sensitization of neuronal cells to oxidative stress with mutated human a-synuclein. J Neurochem 75: 2546-2554
85. Ostrerova-Golts N et al. (2000) The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20: 6048-6054
86. Smith WW et al. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 102: 18676-18681
87. Paxinou E et al. (2001) Induction of α-synuclein aggregation by intracellular nitrative insult. J Neurosci 21: 8053-8061
88. Darios F et al. (2003) Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12: 517-526
89. Park J et al. (2006) Mitochondrial dysfunction in Drosophile PINK1 mutants is complemented by parkin. Nature 441: 1157-1161
90. Gandhi S et al. (2006) PINK1 protein in normal human brain and Parkinson's disease. Brain 129: 1720-1731
91. Taira T et al. (2004) DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 5: 213-218
92. Choi J et al. (2006) Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 281: 10816-10824
93. Menzies FM et al. (2005) Roles of Drosophila DJ-1 in survival of dopaminergic neurons and oxidative stress. Curr Biol 15: 1578-1582